Navigation Links
Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
Date:1/4/2011

NATICK, Mass., Jan. 4, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today issued the following statement from Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, on an article that was published online today by the Journal of the American Medical Association.  The article reported on a study that found that about 20 percent of patients who received an implantable cardioverter defibrillator (ICD) did not meet evidence-based guidelines for receipt of one.

"Guidelines represent consensus from the scientific community that a given procedure or treatment is beneficial, useful and effective.  Boston Scientific is proud to have sponsored many of the clinical trials that provided the scientific foundation for the guidelines referenced in the JAMA article.

"However, it is important to place these results in their appropriate clinical context.  Sudden cardiac arrest (SCA) is the most common cause of death in the U.S.  About 460,000 Americans die each year from SCA; that is more than lung cancer, breast cancer and HIV-related diseases combined.  Currently, more than a million patients are eligible for an ICD, but only a small percentage of patients actually receive the life-saving device.  In fact, previous studies show that ICDs are used in only 20-40 percent of indicated patients in the U.S.

"Dr. Sana Al-Khatib has made important contributions to addressing the under-utilization of device therapies for the prevention of SCA.  She played a key role in organizing the Sudden Cardiac Arrest Thought Leadership Alliance, a think tank on the issue that met in December 2009.  That meeting led to a recent publication on the issue: "Addressing disparities in sudden cardiac arrest care and the under-utilization of effective therapies."  Its major conclusion was: "Despite overwhelming clinical trial evidence, expert opinion, national guidelines, and a vast array of educational conferences, evidence-based, life-prolonging drug and device therapies continue to be under-utilized, with significant disparities in SCA care and use of ICDs in vulnerable populations, including blacks, women and the elderly."

"It is interesting to note that three of four cases cited in the JAMA article were outside the guidelines solely on the basis of timing, and that many of these patients would have qualified within a matter of weeks or months.

"ICD and cardiac resynchronization therapy defibrillator (CRT-D) therapies have been shown to be cost effective in the MADIT II, COMPANION and SCD-HeFT clinical trial patient populations.  In addition, long-term data from the MADIT II study showed that the life-saving benefits of ICD therapy were sustained at eight years (34 percent relative reduction in the risk of death).  In that trial, one life was saved for every eight patients who received an ICD.

"While ICDs are at times used outside the guidelines, the more fundamental problem is that on the whole, this life-saving therapy is under-utilized, rather than over-utilized."  

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com. CONTACT:

Paul Donovan508-650-8541 (office)508-667-5165 (mobile)Media RelationsBoston Scientific CorporationLarry Neumann508-650-8696 (office)Investor RelationsBoston Scientific CorporationSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporation
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cannabis Science Files Preliminary 14c Information Statement, the Action is to Create a New Class of Common Stock and Issue Dividend
2. PhRMA Statement on Department of Homeland Security Efforts to Crack Down on Counterfeiting Crimes
3. Lilly Statement Regarding President Obamas Meeting With U.S. Business Leaders
4. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
5. ERT Files Shelf Registration Statement
6. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
7. Abbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti
8. Media Statement From Amedisys on Dr. Steven H. Landers NEJM Commentary on the Future of Home Care
9. Statement of Ben Anderson, Esq., Regarding Denial of Wyeths En Banc Petition to Sixth Circuit Court of Appeals in Major Drug Regulation Pre-emption Case
10. Cellectis Publishes Its Financial Statement for the First Half of 2010
11. A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...  Kindred Biosciences, Inc. (NASDAQ: KIN ), a ... of pets, today announced the submission to FDA of ... Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline ... for the control of pyrexia (fever) in horses were ... --> The Chemistry, Manufacturing, and Controls ...
(Date:2/11/2016)...   Health 2.0 , the premiere showcase and ... today " 10 Year Global Retrospective ", a platform ... past ten years.   --> ... has served as the preeminent thought-leader in the health ... technologies, companies, innovators, and patient-activists through an array of ...
(Date:2/11/2016)... , Feb. 11, 2016  MiMedx Group, Inc. (NASDAQ: ... human amniotic membrane and other birth tissues, human skin ... develop and market advanced products and therapies, announced today ... 2016 Global Healthcare Conference in New York ... CEO, Michael J. Senken , Chief Financial Officer ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , Feb. ... , As Winston Churchill said, “Those who don’t learn from history are doomed to repeat ... when they come knocking this year. But that takes time. , Take a close ...
(Date:2/12/2016)... ... ... Each year, the American Physical Therapy Association (APTA) offers a Combined Sections ... Center. Almost 10,000 physical therapists across the country are expected to attend this annual ... chosen field and network with their colleagues. As in years past, HydroWorx is ...
(Date:2/12/2016)... ... , ... Coco Libre, the maker of coconut water beverages with a purpose, ... Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut Water, ... gifting suite, held this year at the W Hollywood Hotel, has become a pre-show ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center for Healthcare ... Hospital on April 5-7. The series is a multi-day, multi-workshop event designed to ... cover a broad range of topics, including coaching skills, the scientific method of ...
(Date:2/12/2016)... PITTSBURGH, Pa. (PRWEB) , ... February 12, 2016 , ... ... space heaters. , This winter the West Penn Burn Center, part of ... Fire Company #1, to bring you the “Space Heaters Need Space” campaign. ...
Breaking Medicine News(10 mins):